Buy AOD-9604 hGH Fragment Research Peptide | Koi Aminos
KOIAMINOS
3rd PartyLab Tested
COAVerified
GMPAligned
AOD-9604 research peptide
Lyophilized powder

AOD-9604 hGH Fragment 176-191 Research Peptide

hGH Fragment 176–191

AOD-9604 isolates the lipolytic region of hGH - the 16-amino-acid C-terminal fragment (176–191) that activates β3-adrenergic signaling without touching the GH receptor or IGF-1.

Size: 10mg

$69.95/ 10mg≥99% HPLC
Buy Now on Koi Peptides - $69.95

3rd Party

Lab Tested

Fast 2–5

Day Shipping

COA

Publicly Available

For Research Use Only. Not for human or animal use. Not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively for laboratory and analytical research purposes.

CAS Number

221231-10-3

Molecular Weight

1815.12 g/mol

Full-length hGH activates the GH receptor and drives IGF-1 - which is exactly what you don't want when you're studying lipolysis in isolation. The two signaling pathways are inseparable in native hGH. AOD-9604 solves that problem.

AOD-9604 is a 16-amino-acid synthetic fragment of human growth hormone (residues 176–191) with an N-terminal tyrosine modification that improves proteolytic stability. It activates the β3-adrenergic receptor pathway - driving adipocyte lipolysis, free fatty acid release, and fatty acid oxidation - without engaging the classical GH receptor and without stimulating IGF-1. That clean separation is what makes it the reference compound for isolating the lipolytic mechanism in GH-class research.

We supply AOD-9604 at ≥99% HPLC purity as lyophilized powder. CAS 221231-10-3, MW 1815.12 g/mol, Cys7–Cys14 disulfide bond intact - verified by LC-MS. Lot-specific COA includes HPLC, LC-MS, and endotoxin. For in vitro laboratory research use only.

Key Takeaways

→Lipolysis without IGF-1 - β3-adrenergic pathway activation with zero GH receptor engagement: the key research advantage over full-length hGH
→16-aa hGH C-terminal fragment (residues 176–191) with N-terminal Tyr modification for proteolytic stability
→Cys7–Cys14 disulfide bond intact - verified by LC-MS; avoid strongly reducing conditions during reconstitution
→CAS 221231-10-3, MW 1815.12 g/mol; ≥99% HPLC; COA includes endotoxin testing, not just purity
→The IGF-1-negative control your GH-axis research needs: same hGH origin, entirely different signaling pathway

Key Scientific Specifications

16-amino-acid synthetic hGH fragment 176–191 with N-terminal Tyr modification for proteolytic stability
CAS 221231-10-3 · MW 1815.12 g/mol · Cys7–Cys14 disulfide bond intact (LC-MS verified)
≥99% purity by HPLC; identity confirmed by LC-MS; lyophilized acetate salt
Does not engage the classical GH receptor - no IGF-1 stimulation in published cell-based assays
β3-adrenergic receptor pathway activation for adipocyte lipolysis and fatty acid oxidation research
Lot-specific COA: HPLC purity, LC-MS identity, endotoxin testing

Research-Referenced Attributes

Based on published preclinical and clinical literature; not therapeutic claims. For laboratory research use only.

Lipolysis pathway isolation: β3-adrenergic receptor activation without GH receptor engagement - the defining research feature separating AOD-9604 from full-length hGH
IGF-1-negative control in GH/IGF-1 axis studies - same C-terminal hGH origin as growth hormone, entirely distinct signaling pathway
Adipocyte lipolysis assays: glycerol release and free fatty acid output measurements in β3-adrenergic research models
Fatty acid oxidation and energy expenditure pathway research: mitochondrial fatty acid utilization in AOD-9604-stimulated cell models
Comparative studies with unmodified hGH 176–191 fragment: N-terminal Tyr modification stability effects on proteolytic clearance
Complementary to MOTS-c for parallel energy expenditure and metabolic signaling research models

Also in This Research Area

Researchers working with AOD-9604 frequently also order MOTS-c mitochondrial peptide for parallel energy expenditure and metabolic signaling research, and GLP-2 TZ (tirzepatide-class) for GLP-receptor agonist comparison against β3-adrenergic models. Both are available as lyophilized research-grade peptides on the Koi Aminos research peptide marketplace.

Related Compounds

GLP-3 RT

GLP-3 RT

Single and dual GLP-1 agonists leave GCGR activation on the table. GLP-3 RT (Retatrutide) hits all three - GLP-1R, GIPR, and GCGR - the only way to model true triple-receptor crosstalk.

$89.95–$449.95View
GLP-3 R

GLP-3 R

GLP-3R is the lipidated variant - a 39-amino-acid GLP-1R/GIPR/GCGR triagonist with a fatty acid conjugate that extends half-life and alters receptor-binding kinetics vs. unlipidated analogs.

$89.95–$449.95View